**Introduction**

The diagnosis of parathyroid carcinoma before or during surgery is challenging, especially when the tumor occurs in an unusual location. When this cancer occurs within the thyroid gland, preoperative imaging studies including ultrasound, CT scan, and sestamibi scan have a limited role in distinguishing parathyroid carcinoma from thyroid nodule or benign parathyroid disease. A 53-year-old male was referred to our hospital for assessment of hypercalcemia. He had suffered from chronic kidney disease for 13 years. A 2.5×1.5 cm hypoechoic nodule was noted in the left thyroid gland on ultrasonography, and it showed increased uptake on the sestamibi scan. Fine needle aspiration biopsy revealed it to be a parathyroid lesion, which was confirmed by surgery as parathyroid carcinoma completely surrounded by normal thyroid parenchyma. Because ultrasonography and aspiration cytology have only a limited role in distinguishing parathyroid carcinoma from thyroid neoplasm, suspicion of parathyroid carcinoma before or during surgery through careful examination can lead to complete resection at the initial surgery.

When parathyroid carcinoma occurs in the thyroid gland, it is very difficult to diagnose before surgery because imaging studies and aspiration cytology cannot distinguish parathyroid carcinoma from thyroid nodule or benign parathyroid disease. A 53-year-old male was referred to our hospital for assessment of hypercalcemia. He had suffered from chronic kidney disease for 13 years. A 2.5×1.5 cm hypoechoic nodule was noted in the left thyroid gland on ultrasonography, and it showed increased uptake on the sestamibi scan. Fine needle aspiration biopsy revealed it to be a parathyroid lesion, which was confirmed by surgery as parathyroid carcinoma completely surrounded by normal thyroid parenchyma. Because ultrasonography and aspiration cytology have only a limited role in distinguishing parathyroid carcinoma from thyroid neoplasm, suspicion of parathyroid carcinoma before or during surgery through careful examination can lead to complete resection at the initial surgery.

**Key Words** Chronic kidney disease · Hyperparathyroidism · Parathyroid carcinoma · Thyroid nodule.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Intrathyroidal Parathyroid Carcinoma

Kim MK, et al.

A 53-year-old man was referred to our institution with hypercalcemia with hyperparathyroidism. He suffered from chronic fatigue and multiple joint pain. He had diabetes, hypertension, and chronic kidney disease from 13 years ago and was on hemodialysis. A 1.5×1.5 cm firm mass was palpated at the left lobe of the thyroid gland on physical examination, but he reported no problems with his voice or swallowing. Laboratory tests showed an elevated blood urea nitrogen of 65 mg/dL (reference range, 7–20), a creatinine of 10.2 mg/dL (reference range, 0.5–1.4), a serum calcium of 9.7 mg/dL (reference range, 8.2–10.7) and a low phosphate level of 7.0 mg/dL (reference range, 8.4–10.2). Intact parathyroid hormone (PTH) level was markedly elevated at 3115 pg/mL (reference range, 15–55), but thyroid function tests were within normal ranges. Normal 24-hour urinary catecholamines, calcitonin, and pituitary function excluded multiple endocrine neoplasia.

On thyroid neck ultrasonography, a 2.0×1.5 cm lobulated hypoechogenic lesion with rim calcification was found in the middle portion of the left thyroid gland (Fig. 1). FNAB was done at this lesion and showed findings consistent with a “parathyroid lesion.” Even though the tumor was located within the thyroid gland, FNAB result and markedly increased PTH level suggested parathyroid tumor. Furthermore, tertiary parathyroid hyperplasia could not be excluded because the patient had chronic kidney disease for a long time and was on hemodialysis. So, we did 99mTc-sestamibi parathyroid scan and it showed increased uptake at the left side of the thyroid gland on 10-minute and 2-hour delayed images (Fig. 2).

So, thyroid lobectomy or parathyroidectomy was planned. Because parathyroid gland hyperplasia could not be excluded, we used midline approach by dividing strap muscles for four gland exploration. A 2.5×1.5 cm mass was found in the left lobe of the thyroid gland intraoperatively, which was located within the thyroid gland and surrounding thyroid gland tissue was grossly intact. The left inferior parathyroid gland could not be identified, but the other 3 parathyroid glands were grossly intact. Therefore, a small piece of the left superior parathyroid gland was obtained and was found to be normal parathyroid gland on frozen biopsy. So, left thyroid lobectomy was performed because the tumor was located within the thyroid gland and parathyroid carcinoma was suspected due to markedly high parathyroid hormone level. Several slightly enlarged lymph nodes in the left paratracheal region were harvested (Fig. 3). The thyroid specimen was sent to the pathology department for frozen biopsy and was revealed to be a “parathyroid lesion” confined to the thyroid gland. Permanent biopsy revealed that the 1.8×1.3 cm mass...
was parathyroid carcinoma completely surrounded by normal thyroid gland tissue. It consisted of chief cells with moderate dysplasia and had invaded into the thyroid gland parenchyma through the tumor capsule (Fig. 4). However, there was no lymph node metastasis. PTH dropped to 75 pg/mL on the first postoperative day. Postoperative care including oral vitamin D and calcium supplements with calcium gluconate injections were provided to prevent hypocalcemic symptoms from hungry bone syndrome. Six days after surgery, the patient was discharged without sequelae. PTH increased to 107 pg/mL during the following year, as determined at an outpatient clinic, but it was 149 pg/mL at the last visit in 3 years after surgery. Moreover, there was no evidence of recurrence on imaging studies including ultrasonography, CT scan, 18F-fluorodeoxyglucose positron emission tomography (PET) scan, and sestamibi scan. Therefore, the patient was followed with medical treatment only, because the increased PTH was attributable to chronic kidney disease rather than recurrence of parathyroid carcinoma.

**Discussion**

Parathyroid carcinoma is a very rare cancer that accounts for 0.005% of all cancers. The incidence in patients presenting with primary hyperparathyroidism ranges from less than 0.5% to 3%.\(^4\,^5\)

Clinical and laboratory findings may suggest parathyroid carcinoma, however, these findings are nonspecific. Biochemically, the degree of hypercalcemia is more marked in patients with carcinoma (3.75–4.0 mmol/L) than in benign primary hyperparathyroidism (2.7–2.9 mmol/L).\(^6\) In case of parathyroid carcinoma, the PTH levels are also significantly higher, reported to be greater than 5 to 10 times the normal range. In contrast to benign primary hyperparathyroidism, parathyroid carcinoma patients usually present with palpable mass and end-organ diseases such as osteitis fibrosa cystica, nephrolithiasis and renal and bone disease.\(^7\,^8\) FNAB for parathyroid lesions is helpful in identifying or at least suspecting parathyroid origin in unusually located nodules, because imaging studies including ultrasound, CT, and sestamibi scan have

---

**Fig. 4.** Pathologic findings. The gross cut surface shows a yellowish irregular mass confined to the thyroid gland (A). An encapsulated mass was found in low magnification view (B: H&E stain, ×40). Tumor cells invading into the thyroid gland parenchyma through the capsule (C: H&E stain, ×100). The mass consists of chief cells with moderate dysplasia and is compatible with parathyroid carcinoma (D: H&E stain, ×400). H&E: hematoxylin and eosin.
little role in the diagnosis of parathyroid carcinoma, although they are helpful in localization.

However, differentiating parathyroid carcinoma from adenoma may be impossible on cytology, and parathyroid carcinoma can be confused with several thyroid lesions because they have overlapping cytologic features and some cytomorphic similarities such as tissue fragments with papillary architecture, epithelial cells arranged in a microfollicular pattern, and colloid-like material in the background. Moreover, the presence of oncocytic cells and naked nuclei of chief cells in the parathyroid are hard to distinguish from Hurthle cells and lymphocytes, respectively. Therefore, the differential diagnosis should include not only parathyroid adenoma and parathyroid hyperplasia, but also papillary thyroid carcinoma, anaplastic thyroid cancer, and even metastatic renal cell carcinoma.

Moreover, histologic findings alone are not sufficient for diagnosis of parathyroid carcinoma without malignant histologic features of capsular or neurovascular invasions and/or metastases. The generally accepted histopathologic features of parathyroid carcinoma include trabecular architecture, mitotic figures, thick fibrous bands, and capsular and blood vessel invasion. Immunohistochemical staining for Ki-67, PRAD1/Cyclin D1, p27, and parafibromin is reported to be helpful for diagnosis of parathyroid carcinoma. Unusual location of the parathyroid also complicates the diagnosis of parathyroid carcinoma. Parathyroid carcinoma can occur anywhere that ectopic parathyroid glands can be located. Several previous studies have reported that parathyroid glands are found in an ectopic location 6% to 22% of the time, and these can be one of the four parathyroid glands or a supernumerary gland. Their locations vary and can include the retro/parasophageal space, the mediastinum, intrathyMIC, intrathyroidal sites, the carotid sheath, and in a high undescended cervical position.

The intrathyroidal parathyroid gland is defined as a gland surrounded by thyroid tissue and should be differentiated from subcapsular parathyroid glands. The incidence of intrathyroidal parathyroid gland ranges from 0.5% to 4% and might be higher in patients with hyperparathyroidism. The origin of intrathyroidal parathyroid gland is not fully understood, but it can be either superior or inferior or even supernumerary.

Embryologically, the superior parathyroid gland can be included within the thyroid during the fusion of the ultimobranchial bodies with the median thyroid rudiment. However, some authors found the intrathyroid parathyroid gland located in the lower third of the thyroid lobe, which should be considered as an inferior parathyroid gland.

To the best of our knowledge, only 14 cases of intrathyroidal parathyroid carcinoma have been reported (Table 1). All of these cases presented with hypercalcemia with or without a neck mass. The PTH level was higher than 200 pg/mL in all cases, and some of them were higher than 1000 pg/mL. Sestamibi scan showed increased uptake in the respective lobe for most cases. FNAB was performed in seven cases, and most of them were misinterpreted as a follicular thyroid lesion or poorly differentiated thyroid carcinoma. Parathyroid lesion was reported in only 2 of these cases, and none of the cases had suspected parathyroid carcinoma on FNAB. Frozen biopsy results were described in 6 cases, and parathyroid carcinoma was suspected in only 2 cases. Oncologic outcomes were mentioned in 12 cases, none of which experienced recurrence, although the follow-up period was too short in most cases (1 month–5 years).

As there is no reliable preoperative diagnostic tool for parathyroid carcinoma, suspicion of parathyroid carcinoma preoperatively or intraoperatively is important for establishing proper surgical strategy. Although laboratory findings alone cannot distinguish parathyroid carcinoma from other hyperfunctioning lesions, PTH level in carcinoma is usually higher than in benign parathyroid lesion. The present case showed a high PTH level of 3115 pg/mL. We could not confirm parathyroid carcinoma even on frozen biopsy in this case, but we removed the entire left thyroid and suspicious lymph nodes.

Patients with parathyroid carcinoma should undergo a comprehensive excision at the time of initial surgery. Complete resection frequently requires excision of the ipsilateral thyroid lobe, overlying strap muscle, and adjacent soft tissues. Because pathologic confirmation of parathyroid carcinoma is not always possible during surgery, clinical findings such as preoperative imaging, PTH level or intraoperative finding is important. Because occult lymphatic metastasis is not common, prophylactic neck dissection is not recommended.

Parathyroid carcinoma is known as a slow-growing and often indolent but progressive tumor. It invades surrounding tissues and metastasizes both hematogenously and, less commonly, via lymphatics. Complete tumor resection is important for improving prognosis. A higher 5-year survival rate was reported when ipsilateral hemithyroidectomy accompanied the initial resection (90.0% with hemithyroidectomy and 82.5% without hemithyroidectomy). A national cancer data base study reported 5-and 10-year overall survival rates of 82.3%
| Case                  | Age/sex | Presentation                                                                 | Past history                  | PTH level | Tumor location/size | Cytologic diagnosis | Frozen biopsy | Treatment                                                   | Outcome, f/u |
|-----------------------|---------|-------------------------------------------------------------------------------|--------------------------------|-----------|---------------------|---------------------|--------------|-----------------------------------------------------------|---------------|
| Ernst et al.          | 52/F    | Hyperparathyroidism, hypercalcemia                                            | Nephrolithiasis               | -         | Lt. thyroid/2.5 cm  | -                   | -            | Thyroid lobectomy                                          | NED, 4 months |
| Crescenzo et al.      | 60/F    | Left neck mass, hyperparathyroidism, hypercalcemia                           | Gastric ulcer, nephrolithias  | 205       | Lt. thyroid/1.5 cm  | Follicular thyroid neoplasm | Parathyroid carcinoma | Thyroid lobectomy, isthmusectomy | NED, 8 months |
| Kirstein and Ghosh    | 74/M    | Hyperparathyroidism                                                           | CKD, hypertension, CHF, COPD  | 652       | Lt. thyroid/-       | -                   | -            | Thyroid lobectomy                                          | -             |
| Schmidt et al.        | 76/F    | Hyperparathyroidism, hypercalcemia                                            | Asthma, HTN, DM, CAD          | 580       | Rt. sup. thyroid/3.2 cm | -                   | Parathyroid carcinoma | Total thyroidectomy | NED, 1 year    |
| Hussein et al.        | 63/F    | Hyperparathyroidism, hypercalcemia, body aches, fatigue, constipation, reflux disease | HTN, nephrolithiasis, depression, renal insufficiency | 760       | Lt. thyroid/6.0 cm  | -                   | -            | Thyroid lobectomy                                          | NED, >1 month |
| Foppiani et al.       | 67/F    | Hyperparathyroidism, hypercalcemia, multinodular goiter                      | Lt. hemithyroidectomy for nodular goiter | 721       | Rt. thyroid/3.0 cm  | -                   | Thyroid lesion with pleomorphism | Total thyroidectomy | NED, 5 years    |
| Temmim et al.         | 63/F    | Hyperparathyroidism, hypercalcemia                                            | Hypertension, nephrolithias   | -         | Lt. thyroid/6.0 cm  | -                   | Benign thyroid tissue | Total thyroidectomy | NED, 2 years    |
| Herrera-Hernández et al. | 14/F   | Hyperparathyroidism, hypercalcemia                                            | Polymyalgia, muscle atrophy, joint deformity | 2792      | Right thyroid/2.5 cm | -                   | -            | Thyroid lobectomy                                          | NED, 18 months |
| Kruljac et al.        | 40/M    | Hyperparathyroidism, hypercalcemia                                            | Nephrolithiasis               | 989       | Lt. thyroid/3.1 cm  | Poorly differentiated thyroid follicular carcinoma | Medullary thyroid carcinoma | Total thyroidectomy, MRND | NED, 10 months |
| Vila Duckworth et al. | 51/F    | Hyperparathyroidism, hypercalcemia                                            | -                              | 579       | Rt. Inf. thyroid/1.4 cm | Indeterminate for follicular neoplasm | -             | Total thyroidectomy, parathyroidectomy | NED, 2.5 years |
| Lee et al.            | 59/F    | Hyperparathyroidism, hypercalcemia                                            | MEN type I                     | 248       | Rt. thyroid/2.1 cm  | Follicular lesion | -            | Thyroid lobectomy                                          | -             |
In this case, the left inferior parathyroid gland could not be identified during the operation, and a thyroid nodule was reported as a parathyroid lesion on the frozen biopsy. Thyroid lobectomy and left paratracheal lymph node biopsy were performed. Because the tumor was confined to the thyroid gland and parathyroid hormone levels remained stable but high, we followed the patient without adjuvant therapy. During the 3 years of follow-up, PTH increased to around 120 pg/mL due to chronic kidney disease, but there was no evidence of recurrence on imaging studies including ultrasonography, CT scan, PET/CT scan, and sestamibi scan.

In conclusion, parathyroid lesion including carcinoma should be suspected when PTH is substantially increased, although parathyroid carcinoma is uncommon. Clinicians should be aware that masses in unusual locations, even in the thyroid gland, might be parathyroid carcinoma, because parathyroid glands can exist at various ectopic locations. Because there are no reliable preoperative diagnostic tools for parathyroid carcinoma, suspicion of parathyroid carcinoma before or during surgery is important. Suspicion and careful examination can lead to complete resection at the initial surgery, which is important for the best chance of cure.

Acknowledgments

None.

ORCID

Yong Bae Ji  https://orcid.org/0000-0002-0182-7865

REFERENCES

1) Shi C, Guan H, Qi W, Ji J, Wu J, Yan F, et al. Intrathyroidal parathyroid adenoma: Diagnostic pitfalls on fine-needle aspiration: Two case reports and literature review. Diagn Cytopathol 2016;44(11):921-925.
2) Paker I, Yilmazer D, Yandakci K, Arikok AT, Alper M. Intrathyroidal oncocytic parathyroid adenoma: A diagnostic pitfall on fine-needle aspiration. Diagn Cytopathol 2010;38(11):833-6.
3) Kim BS, Ryu HS, Kang KH, Park SJ. Parathyroid carcinoma in tertiary hyperparathyroidism. Asian J Surg 2016;39(4):255-9.
4) Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: A National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86(3):538-44.
5) Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001;86(2):485-93.
6) Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid carcinoma: Analysis of an experience of 19 cases. J Surg Oncol 2004;88(4):223-8.
7) Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: An update and review. World J Surg 1991;15(6):738-44.
8) Koea JB, Shaw JH. Parathyroid cancer: Biology and management.
Surg Oncol 1999;8(3):155-65.
9) Bondeson L, Bondeson AG, Nissborg A, Thompson NW. Cytopathological variables in parathyroid lesions: A study based on 1,600 cases of hyperparathyroidism. Diagn Cytopathol 1997; 16(6):476-82.
10) Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, et al. Parathyroid neoplasms: Clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2003; 34(1):54-64.
11) Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004;10(19):6629-37.
12) Roy M, Mazeh H, Chen H, Sippel RS. Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg 2013;37(1):102-6.
13) Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg 2006;191(3):418-23.
14) Thompson NW, Eckhauser FE, Harness JK. The anatomy of primary hyperparathyroidism. Surgery 1982;92(5):814-21.
15) Wang C. The anatomic basis of parathyroid surgery. Ann Surg 1976;183(3):271-5.
16) Wheeler MH, Williams ED, Wade JS. The hyperfunctioning intrathyroidal parathyroid gland: A potential pitfall in parathyroid surgery. World J Surg 1987;11(1):110-4.
17) Ernst M, Lippmann M, Fleige B. [Primary hyperparathyroidism in intrathyroid parathyroid cancer]. Zentralbl Chir 1993;118(11):682-5.
18) Crescenzo DG, Shabahang M, Garvin D, Evans SR. Intrathyroidal parathyroid cancer presenting as a left neck mass. Thyroid 1998; 8(7):597-9.
19) Kirstein LJ, Ghosh BC. Intrathyroidal parathyroid carcinoma. J Surg Oncol 2001;77(2):136-8.
20) Schmidt JL, Perry RC, Philippens LP, Wu HH. Intrathyroidal parathyroid carcinoma presenting with only hypercalcemia. Otolaryngol Head Neck Surg 2002;127(4):352-3.
21) Hussein WI, El-Maghraby TA, Al-Sanea O. Hyperfunctioning intrathyroidal parathyroid carcinoma. Saudi Med J 2006;27(8): 1226-9.
22) Foppiani L, Del Monte P, Sartini G, Arlandini A, Quilici P, Bandelloni R, et al. Intrathyroidal parathyroid carcinoma as cause of hypercalcemia and pitfall of localization techniques: Clinical and biologic features. Endocr Pract 2007;13(2):176-81.
23) Temmim L, Sinowitz F, Hussein WI, Al-Sanea O, El-Khodary H. Intrathyroidal parathyroid carcinoma: A case report with clinical and histological findings. Diagn Pathol 2008;3:46.
24) Herrera-Hernández AA, Aranda-Valderrama P, Díaz-Pérez JA, Herrera LP. Intrathyroidal parathyroid carcinoma in a pediatric patient. Pediatr Surg Int 2011;27(12):1361-5.
25) Krujlac I, Pavic I, Matesa N, Mirosevic G, Marie A, Beejac B, et al. Intrathyroidal parathyroid carcinoma with intrathyroidal metastasis to the contralateral lobe: Source of diagnostic and treatment pitfalls. Jpn J Clin Oncol 2011;41(9):1142-6.
26) Vila Duckworth L, Winter WE, Vaysberg M, Moran CA, Al-Quran SZ. Intrathyroidal parathyroid carcinoma: Report of an unusual case and review of the literature. Case Rep Pathol 2013;2013:198643.
27) Lee KM, Kim EJ, Choi WS, Park WS, Kim SW. Intrathyroidal parathyroid carcinoma mimicking a thyroid nodule in a MEN type 1 patient. J Clin Ultrasound 2014;42(4):212-4.
28) You WY, Han YM, Choi YH. Intrathyroidal parathyroid carcinoma: A case report. J Korean Soc Radiol 2015;72(5):319-23.
29) Tejera Hernández AA, Gutiérrez Giner MI, Vega Benitez V, Fernández San Millan D, Hernández Hernández JR. Intrathyroidal parathyroid carcinoma. A case report and review of literature. Endocrinol Nutr 2016;63(1):46-8.
30) Balakrishnan M, George SA, Rajah SH, Francis IM, Kapila K. Cytological challenges in the diagnosis of intrathyroidal parathyroid carcinoma: A case report and review of literature. Diagn Cytopathol 2018;46(1):47-52.
31) Tae K, Lee YS, Kim KR, Lee HS, Park DW, Park YS, et al. Radiologic diagnosis and surgical treatment of primary hyperparathyroidism. Korean J Otolaryngol-Head Neck Surg 2006;49(7):733-9.
32) Jung EJ, Seo KH, Kim WS, Jung KY. A case of nonfunctioning parathyroid carcinoma. Korean J Otolaryngol-Head Neck Surg 2002;45(3):303-5.
33) Kleinpeter KP, Lovato JF, Clark PB, Wooldridge T, Norman ES, Bergman S, et al. Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol 2005;12(3):260-6.
34) Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, et al. Parathyroid carcinoma: An update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol 2015;22(12):3990-5.